既往使用合成代谢类固醇男性的生育结局
回顾性分析2018至2022年45例因合成代谢类固醇使用导致无精子症或严重少精子症男性,采用停用睾酮替代并联合枸橼酸氯米芬与人绒毛膜促性腺激素至少3至6个月的治疗方案,评估精子参数恢复及妊娠结局。
要点
- 45例中23例(51.1%)初始为无精子症,联合治疗中位5个月后仅1例(5.6%)达正常精子症。
- 24对随访夫妇中9对(37.5%)获得后续妊娠,其中6对(66.7%)自然受孕。
- logistic回归未发现改善精子参数或成功妊娠的显著预测因素。
核心结论
- 尽管采用适当治疗方案,相当比例有合成代谢类固醇使用史的男性仍持续存在严重少精子症,超过半数在治疗6个月后精液参数改善有限,仅少数达到正常精子症。
- 需要进一步研究探索有合成代谢类固醇使用史男性精子参数改善和成功妊娠结局的预测因素。
研究设计与样本
- 回顾性队列分析,纳入2018年至2022年间有合成代谢类固醇使用史且主诉不育的男性45例(中位年龄37岁,IQR 32-45)。
- 暴露因素为标准化治疗方案:停用睾酮替代疗法并联合使用枸橼酸氯米芬和人绒毛膜促性腺激素至少3至6个月。
主要发现
- 既往睾酮使用中位时长4年(IQR 1.3-10),最常见方式为注射治疗(43.5%)和口服治疗(34.8%)。
- 初始精子浓度中位数为0百万/cc(IQR 0-1.15),23例(51.1%)初始表现为无精子症。
- 联合人绒毛膜促性腺激素/氯米芬治疗中位时长5个月(IQR 3-12)。
- 初始无精子症者23例中,5例失访,6例(33.3%)转为严重少精子症(<5百万/cc),6例(33.3%)转为少精子症(<15百万/cc),1例(5.6%)转为正常精子症(>15百万/cc),5例(27.8%)治疗6个月后仍为无精子症。
- 24对随访应答夫妇中9对(37.5%)获得成功后续妊娠,其中3对(33.3%)使用辅助生殖技术,6对(66.7%)自然受孕。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study sperm parameters recovery and fertility outcomes in men with azoospermia or severe oligospermia caused by anabolic steroid use who underwent a standardized treatment regimen for spermatogenesis recovery. DESIGN AND SUBJECTS: A retrospective analysis of a cohort of men with a prior history of anabolic steroid use and infertility complaints (between 2018 and 2022) was conducted. EXPOSURE: The standardized treatment approach involved discontinuing testosterone replacement therapy and administering a combination regimen of clomiphene citrate and human chorionic gonadotropin for a minimum of 3 to 6 months. MAIN OUTCOME MEASURES: The main outcome measures included changes in sperm parameters, predominantly sperm concentration, and subsequent pregnancy outcomes. RESULTS: A total of 45 men (median age 37 years, IQR 32-45) met the inclusion criteria for this analysis. Median duration of prior T use was 4 years (IQR 1.3-10), with the 2 most common modalities consisting of injection therapy (43.5%) and oral therapy (34.8%). The median initial sperm concentration was 0 million/cc (IQR 0-1.15), and 23 (51.1%) men initially presented with azoospermia. The median duration of combination human chorionic gonadotropin/clomid therapy was 5 months (IQR 3-12). In initially azoospermic men (N: 23), 5 were lost to follow-up, 6 (33.3%) progressed to severe oligospermia (<5 million/cc), 6 (33.3%) to oligospermia (<15 million/cc), 1 (5.6%) to normozoospermia (>15 million/cc), and 5 (27.8%) remained azoospermic after medical treatment for 6 months. Among the 24 couples who responded to the follow-up call, a total of 9 (37.5%) achieved a successful subsequent pregnancy. Of these, 33.3% (3 couples) used assisted reproductive technology, whereas 66.7% (6 couples) conceived naturally. On logistic regression analysis, no significant predictors for improved sperm parameters or successful pregnancy were identified. CONCLUSION: Despite appropriate treatment regimens, a significant proportion of men with a prior history of anabolic steroid use continue to exhibit severe oligospermia, with more than half showing limited improvement in semen parameters after 6 months of treatment. Only a fraction of men achieves normozoospermia after treatment. Further research is needed to explore predictors for improved sperm parameters and successful pregnancy outcomes in men with a history of anabolic steroid use.
引用
- Ledesma BR, Weber A, Venigalla G, et al. Fertility outcomes in men with prior history of anabolic steroid use. Fertil Steril. 2023. PMID: 37769866. doi:10.1016/j.fertnstert.2023.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。